Now Creative Biolabs provides the Tau degradation assay to identify inhibitors for Tau fibrillization in mutant Tau overexpressed cells. According to the Tau degradation assay, it is possible to verify whether the compound can degrade tau protein in human cells. The compound's ability to cross the blood-brain barrier (BBB) can then be further assessed by in vivo experiments. Aggregation of tau proteins, especially hyperphosphorylated tau proteins, may contribute to tauopathies in AD. Therefore, the degradation of tau protein provides new ideas for the treatment of neurological diseases such as AD.